Načítá se...
Population pharmacokinetics–pharmacodynamics of sunitinib in pediatric patients with solid tumors
PURPOSE: The safety profile of sunitinib in children, including the impact of sunitinib exposure on safety endpoints, was assessed using population pharmacokinetic (PK) and pharmacokinetic–pharmacodynamic (PK–PD) models. METHODS: Data were from two clinical studies in 59 children with solid tumors (...
Uloženo v:
| Vydáno v: | Cancer Chemother Pharmacol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer Berlin Heidelberg
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7417410/ https://ncbi.nlm.nih.gov/pubmed/32623479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04106-z |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|